Literature DB >> 25389904

Fenofibrate enhances barrier function of endothelial continuum within the metastatic niche of prostate cancer cells.

Katarzyna Piwowarczyk1, Ewa Wybieralska, Jarosław Baran, Julia Borowczyk, Paulina Rybak, Milena Kosińska, Anna Julia Włodarczyk, Marta Michalik, Maciej Siedlar, Zbigniew Madeja, Jerzy Dobrucki, Krzysztof Reiss, Jarosław Czyż.   

Abstract

OBJECTIVE: Extravasation of circulating cancer cells is an important step of the metastatic cascade and a potential target for anti-cancer strategies based on vasoprotective drugs. Reports on anti-cancer effects of fenofibrate (FF) prompted us to analyze its influence on the endothelial barrier function during prostate cancer cell diapedesis. RESEARCH DESIGN AND METHODS: In vitro co-cultures of endothelial cells with cancer cells imitate the 'metastatic niche' in vivo. We qualitatively and quantitatively estimated the effect of 25 μM FF on the events which accompany prostate carcinoma cell diapedesis, with the special emphasis on endothelial cell mobilization.
RESULTS: Fenofibrate attenuated cancer cell diapedesis via augmenting endothelial cell adhesion to the substratum rather than through the effect on intercellular communication networks within the metastatic niche. The inhibition of endothelial cell motility was accompanied by the activation of PPARα-dependent and PPARα-independent reactive oxygen species signaling, Akt and focal adhesion kinase (FAK) phosphorylation, in the absence of cytotoxic effects in endothelial cells.
CONCLUSIONS: Fenofibrate reduces endothelial cell susceptibility to the paracrine signals received from prostate carcinoma cells, thus inhibiting endothelial cell mobilization and reducing paracellular permeability of endothelium in the metastatic niche. Our data provide a mechanistic rationale for extending the clinical use of FF and for the combination of this well tolerated vasoactive drug with the existing multidrug regimens used in prostate cancer therapy.

Entities:  

Keywords:  PPARα; endothelium; fenofibrate; invasion; prostate cancer; reactive oxygen species

Mesh:

Substances:

Year:  2014        PMID: 25389904     DOI: 10.1517/14728222.2014.981153

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  8 in total

1.  Fenofibrate-induced mitochondrial dysfunction and metabolic reprogramming reversal: the anti-tumor effects in gastric carcinoma cells mediated by the PPAR pathway.

Authors:  Lulu Chen; Jin Peng; You Wang; Huangang Jiang; Wenbo Wang; Jing Dai; Meng Tang; Yan Wei; Hao Kuang; Guozeng Xu; Hui Xu; Fuxiang Zhou
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

2.  Fenofibrate Reduces the Asthma-Related Fibroblast-To-Myofibroblast Transition by TGF-Β/Smad2/3 Signaling Attenuation and Connexin 43-Dependent Phenotype Destabilization.

Authors:  Milena Paw; Dawid Wnuk; Dominika Kądziołka; Aleksandra Sęk; Sławomir Lasota; Jarosław Czyż; Zbigniew Madeja; Marta Michalik
Journal:  Int J Mol Sci       Date:  2018-08-29       Impact factor: 5.923

3.  Fenofibrate potentiates chemosensitivity to human breast cancer cells by modulating apoptosis via AKT/NF-κB pathway.

Authors:  Jianguo Sun; Zhibao Zheng; Qi Chen; Yin Pan; Mingming Quan; Yuechu Dai
Journal:  Onco Targets Ther       Date:  2019-01-23       Impact factor: 4.147

4.  The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas.

Authors:  Wei Zhu; Hongyang Zhao; Fenfen Xu; Bin Huang; Xiaojing Dai; Jikui Sun; Alphonce M K Nyalali; Kailiang Zhang; Shilei Ni
Journal:  BMC Cancer       Date:  2021-06-03       Impact factor: 4.430

5.  Methyl Sulfone Blocked Multiple Hypoxia- and Non-Hypoxia-Induced Metastatic Targets in Breast Cancer Cells and Melanoma Cells.

Authors:  Joan McIntyre Caron; Jane McIntyre Caron
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

Review 6.  Anticancer Properties of Fenofibrate: A Repurposing Use.

Authors:  Xin Lian; Gang Wang; Honglan Zhou; Zongyu Zheng; Yaowen Fu; Lu Cai
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

7.  Fenofibrate Interferes with the Diapedesis of Lung Adenocarcinoma Cells through the Interference with Cx43/EGF-Dependent Intercellular Signaling.

Authors:  Katarzyna Piwowarczyk; Edyta Kwiecień; Justyna Sośniak; Eliza Zimoląg; Emiliana Guzik; Jolanta Sroka; Zbigniew Madeja; Jarosław Czyż
Journal:  Cancers (Basel)       Date:  2018-09-28       Impact factor: 6.639

8.  CD44+ cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations.

Authors:  Tomasz Wróbel; Marcin Luty; Jessica Catapano; Elżbieta Karnas; Małgorzata Szczygieł; Katarzyna Piwowarczyk; Damian Ryszawy; Grażyna Drabik; Ewa Zuba-Surma; Maciej Siedlar; Zbigniew Madeja; Martyna Elas; Jarosław Czyż
Journal:  Stem Cells       Date:  2020-09-27       Impact factor: 6.277

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.